Coordinatore | KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
Nazionalità Coordinatore | Sweden [SE] |
Sito del progetto | http://www.cogseu.org/ |
Totale costo | 16˙703˙903 € |
EC contributo | 11˙715˙501 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2007-B |
Funding Scheme | CP-IP |
Anno di inizio | 2009 |
Periodo (anno-mese-giorno) | 2009-05-01 - 2014-01-31 |
# | ||||
---|---|---|---|---|
1 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | coordinator | 1˙301˙573.10 |
2 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 3˙796˙030.50 |
3 |
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
Organization address
address: CALLE MELCHOR FERNANDEZ ALMAGRO 3 contact info |
ES (MADRID) | participant | 2˙300˙650.80 |
4 |
STICHTING HET NEDERLANDS KANKER INSTITUUT
Organization address
address: PLESMANLAAN 121 contact info |
NL (AMSTERDAM) | participant | 1˙087˙739.60 |
5 |
INSTITUTE OF CANCER RESEARCH - ROYAL CANCER HOSPITAL
Organization address
address: Old Brompton Road 123 contact info |
UK (LONDON) | participant | 600˙674.80 |
6 |
DEUTSCHES KREBSFORSCHUNGSZENTRUM
Organization address
address: Im Neuenheimer Feld 280 contact info |
DE (HEIDELBERG) | participant | 545˙487.25 |
7 |
KRAEFTENS BEKAEMPELSE
Organization address
address: Strandboulevarden 49 contact info |
DK (KOEBENHAVN) | participant | 519˙662.80 |
8 |
FOUNDATION FOR GENOMICS & POPULATION HEALTH
Organization address
address: WORTS CAUSEWAY 2 contact info |
UK (CAMBRIDGE) | participant | 490˙132.00 |
9 |
THE UNIVERSITY OF WARWICK
Organization address
address: Kirby Corner Road - University House - contact info |
UK (COVENTRY) | participant | 319˙872.00 |
10 |
LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
SE (LUND) | participant | 201˙534.00 |
11 |
Nome Ente NON disponibile
Organization address
address: STENBACKINKATU 9 contact info |
FI (HELSINKI) | participant | 201˙471.60 |
12 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 170˙906.40 |
13 |
CENTRE ANTICANCEREUX LEON BERARD
Organization address
address: RUE LAENNEC 28 contact info |
FR (LYON) | participant | 136˙884.00 |
14 |
BREAST INTERNATIONAL GROUP - AISBL
Organization address
address: BOULEVARD DE WATERLOO 121 contact info |
BE (BRUXELLES) | participant | 42˙882.30 |
15 |
ANTI CANCER COUNCIL OF VICTORIA
Organization address
address: RATHDOWNE STREET 1 contact info |
AU (CARLTON VICTORIA) | participant | 0.00 |
16 |
QUEENSLAND INSTITUTE OF MEDICAL RESEARCH
Organization address
address: "Herston Road, 300" contact info |
AU (HERSTON) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'The overarching goal of COGS is to identify individuals with an increased risk of breast, ovary and prostate cancer. Furthermore, we will evaluate the effect of inherited genetic variation on tumour characteristics and clinical outcome. We will do this through quantifying the role of genetic and environmental/lifestyle risk in the largest data set ever generated. In all, we will include over 200,000 individuals in the COGS project. We will use detailed knowledge of the architecture of genetic susceptibility and interactions with environmental/lifestyle factors which will result in much more accurate individual risk prediction and improved intervention strategies. We are taking advantage of a unique possibility by incorporating seven existing consortia into one large project – COGS. Members of these consortia have collaborated successfully over the past years and results have been presented in world leading scientific journals such as Nature, Nature Genetics and Journal of the National Cancer Institute. These papers reflect that collaboration has been ongoing and that is has so far been very successful. We will also build on an existing European Commission project, TRANSBIG, thus adding value to already spent money. Results generated through COGS will lead to an improved understanding of the biological processes that underlie carcinogenesis, that in turn could guide new therapeutic strategies. Results will also lead to the development of new tests for risk prediction for breast, ovarian and prostate cancer.'
A better understanding of what factors contribute to the risk of certain types of cancer can help in developing both predictive tools and intervention strategies.
The 'Collaborative oncological gene-environment study' (COGS) project is working to more precisely define the individual risk of disease by taking into account all possible influencing factors. Researchers have five major objectives: to identify genetic variation underlying increased risk for breast, ovarian and prostate cancer; to assess interaction between genetic loci and known or suspected environmental/lifestyle risk factors; to assess whether the link between genetic factors, environmental/lifestyle risk factors and cancer risk is stronger for certain tumour subtypes; to develop comprehensive risk models for these cancers; and to investigate the efficacy and cost-effectiveness of using these risk models in prevention strategies.
Statistical analyses are being used to identify genetic loci through a multi-step procedure, with resulting genotyping results forming the basis for subsequent project activities. Initial work in this EU-funded project has focused on identifying the 200 000 single nucleotide polymorphisms (SNPs) that will be put on the Illumina iSelect chip, to be generated by one of the consortium partners. SNPs, the most common type of genetic variation found in the same biological species, offer information on how genetic make-up is linked to disease development and therapeutic responses.
Datasets have been made up from existing genetic association studies (GWASs) in breast, prostate and ovarian cancer. These will be used to derive estimated genotypes for all subjects.
During the first year of the project, efforts went into quantifying and organising the DNA received from partners all over the world. Actual genotyping has been scheduled to begin when the chip is delivered.
Negotiations have been conducted for the purchase of an iCOGS chip for SNP selection and genotyping. The first cancer chip of its kind, this achievement allows for genotyping across all consortia and provides a means of eliminating candidate SNPs at each locus.
Thanks to advances in methods of data generation, 55 loci (18 loci for breast cancer, 27 for prostate, 6 for ovarian, 4 implicated in various other cancers) have already been examined. Data mining of data released by the 1000 Genomes Project and the Hapmap project have made it possible to compare numbers of the common variants identified.
In work investigating gene-environment interactions placing individuals at risk for cancer, study questionnaires have been uploaded onto the websites of project partners. These links are also provided on the COGS website. Variables for all the risk factors have been coded, with more detailed variables having been defined for more in-depth analysis in subsets to be carried out at a later stage.
As work continues, consortium partners continue to lay the foundations for planned studies in order to fulfil project objectives. COGS researchers expect that as new discoveries are made and environmental/lifestyle factors are identified, the project will succeed in offering explanations for individual variations in disease risk. The results of this project will also lead to enhanced knowledge of the biological processes underlying carcinogenesis. This is important for guiding new therapeutic strategies, as well as for developing tests for risk prediction.